Singapore markets closed
Straits Times Index
3,255.54 +16.51 (+0.51%) S&P 500
3,965.63 -11.90 (-0.30%) Dow
32,470.57 +38.49 (+0.12%) Nasdaq
11,673.18 -95.66 (-0.81%) Bitcoin USD
26,958.19 -427.47 (-1.56%) CMC Crypto 200
590.30 +347.62 (+143.24%)
AZN Oct 2023 80.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 09:54AM EDT. Market open.
| Previous close | 1.4000 |
| Open | 1.3000 |
| Bid | 1.2700 |
| Ask | 1.3900 |
| Strike | 80.00 |
| Expiry date | 2023-10-20 |
| Day's range | 1.3000 - 1.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 335 |
- Zacks
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
- Business Wire
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
WILMINGTON, Del., March 27, 2023--Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.1
- Zacks
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
© 2023 Yahoo. All rights reserved.
